- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Baxter alleged Johnson & Johnson used the Trasylol (aprotinin) safety alert to promote Quixil in a misleading way. The Panel found briefing…
A leavepiece for Acomplia was ruled misleading for implying broader NICE approval than guidance allowed, altering the emphasis of NICE wording on…
GSK challenged Pfizer’s Champix detail aid claims on quit rates, NNT, cost-effectiveness and safety information. The Panel found the data were presented…
A pharmacist challenged comparative efficacy and tolerability claims for Versatis versus pregabalin/gabapentin. The Panel found interim data and SPC references did not…
Cephalon challenged ProStrakan’s claim that Abstral provided rapid relief from 10 minutes. The Panel found the claim inconsistent with the Abstral SPC,…
MHRA complained that a Zoladex (goserelin) journal ad referenced the MHRA. The Panel ruled this breached Clause 9.5 (no exemption applied). AstraZeneca…
A pioglitazone journal ad implied CV event reduction as part of the product’s benefits and called a Takeda-funded meta-analysis “independent”. Breaches of…
A nurse challenged a Ferinject detail aid as inaccurate. The PMCPA found the CosmoFer administration chart and a “Single dose delivery” claim…
Merz’s exhibition claim that Xeomin was “at least as effective as Botox” was ruled misleading because the cited studies were non-inferiority trials…
A professor said a rep refused to leave a Ranexa memory stick unless she saw him, creating an impression of inducement. Breach…
Former rep alleged poor Code training and uncertified Effentora launch materials. PMCPA found breaches for uncertified briefing materials and inadequate/undocumented training, but…
Beacon’s mailing claimed Episenta was bioequivalent to and interchangeable with Epilim Chrono. A neurologist said this conflicted with epilepsy guidance on avoiding…
Anonymous clinician alleged Mycamine advisory boards were promotional and attendees were profiled for follow-up. PMCPA found disguised promotion, inducement via fees, and…
A palliative medicine consultant complained about an Actiq rep’s comments on competitor Abstral. The Panel found misleading/disparaging competitor messaging and inadequate training…
PMCPA ruled a UK journal ad for Seroquel misleading for implying an advantage on weight gain (“favourable weight profile across the full…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.